Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.50 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828795 | 0.85 | CALML3 (0.47) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL542030 | 0.85 | CALML3 (0.67) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL10062439 | 0.85 | CALML3 (0.67) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL542031 | 0.85 | CALML3 (0.67) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL542136 | 0.84 | CALML3 (0.47) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL17769240 | 0.84 | CALML3 (0.53) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL17769239 | 0.84 | CALML3 (0.53) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7511097 | 0.82 | GRM2 (0.62) | MAOAGRM2 | |
| SCHEMBL7511100 | 0.82 | GRM2 (0.62) | MAOAGRM2 | |
| SCHEMBL9463574 | 0.82 | GRM2 (0.62) | MAOAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | CALML3 3066/4885MAOA 447/4885MAOB 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.